Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 4.50
ALIM's Cash to Debt is ranked higher than
80% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. ALIM: 4.50 )
ALIM' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 4.5

Equity to Asset 0.28
ALIM's Equity to Asset is ranked lower than
51% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ALIM: 0.28 )
ALIM' s 10-Year Equity to Asset Range
Min: -0.25   Max: 0.3
Current: 0.28

-0.25
0.3
F-Score: 4
Z-Score: -5.70
M-Score: 25.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -505.63
ALIM's Operating margin (%) is ranked lower than
53% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. ALIM: -505.63 )
ALIM' s 10-Year Operating margin (%) Range
Min: -1837.82   Max: -1837.82
Current: -505.63

Net-margin (%) -595.42
ALIM's Net-margin (%) is ranked lower than
53% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. ALIM: -595.42 )
ALIM' s 10-Year Net-margin (%) Range
Min: -2469.5   Max: -2469.5
Current: -595.42

ROE (%) -460.77
ALIM's ROE (%) is ranked lower than
56% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. ALIM: -460.77 )
ALIM' s 10-Year ROE (%) Range
Min: -270.19   Max: -61.59
Current: -460.77

-270.19
-61.59
ROA (%) -96.50
ALIM's ROA (%) is ranked lower than
55% of the 816 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. ALIM: -96.50 )
ALIM' s 10-Year ROA (%) Range
Min: -329.68   Max: -20.46
Current: -96.5

-329.68
-20.46
ROC (Joel Greenblatt) (%) -1298.46
ALIM's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. ALIM: -1298.46 )
ALIM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14172.99   Max: -1794.68
Current: -1298.46

-14172.99
-1794.68
EBITDA Growth (%) 13.30
ALIM's EBITDA Growth (%) is ranked higher than
80% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. ALIM: 13.30 )
ALIM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 13.3
Current: 13.3

0
13.3
EPS Growth (%) 19.50
ALIM's EPS Growth (%) is ranked higher than
83% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. ALIM: 19.50 )
ALIM' s 10-Year EPS Growth (%) Range
Min: 0   Max: 19.5
Current: 19.5

0
19.5
» ALIM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALIM Guru Trades in Q3 2013

Columbia Wanger 3,016,280 sh (+5.86%)
» More
Q4 2013

ALIM Guru Trades in Q4 2013

Columbia Wanger 3,016,280 sh (unchged)
» More
Q1 2014

ALIM Guru Trades in Q1 2014

Columbia Wanger 3,016,280 sh (unchged)
» More
Q2 2014

ALIM Guru Trades in Q2 2014

Columbia Wanger 1,168,298 sh (-61.27%)
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 33.28
ALIM's P/S is ranked higher than
51% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.73 vs. ALIM: 33.28 )
ALIM' s 10-Year P/S Range
Min: 30.31   Max: 512
Current: 33.28

30.31
512
EV-to-EBIT 0.42
ALIM's EV-to-EBIT is ranked lower than
54% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. ALIM: 0.42 )
ALIM' s 10-Year EV-to-EBIT Range
Min: -8.7   Max: -2.2
Current: 0.42

-8.7
-2.2
Current Ratio 11.28
ALIM's Current Ratio is ranked higher than
96% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. ALIM: 11.28 )
ALIM' s 10-Year Current Ratio Range
Min: 0.59   Max: 11.78
Current: 11.28

0.59
11.78
Quick Ratio 10.95
ALIM's Quick Ratio is ranked higher than
96% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. ALIM: 10.95 )
ALIM' s 10-Year Quick Ratio Range
Min: 0.59   Max: 11.78
Current: 10.95

0.59
11.78

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.59
ALIM's Price/Net Cash is ranked higher than
87% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALIM: 33.59 )
ALIM' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 65.75
Current: 33.59

1.37
65.75
Price/Median PS Value 0.58
ALIM's Price/Median PS Value is ranked higher than
95% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. ALIM: 0.58 )
ALIM' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 8
Current: 0.58

0.61
8
Earnings Yield (Greenblatt) 238.10
ALIM's Earnings Yield (Greenblatt) is ranked lower than
51% of the 794 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ALIM: 238.10 )
ALIM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: 238.1

Forward Rate of Return (Yacktman) -76.48
ALIM's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. ALIM: -76.48 )
ALIM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -158.3   Max: -52
Current: -76.48

-158.3
-52

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ASZ.Germany
Alimera Sciences, Inc., was incorporated in Delaware on June 4, 2003. It is a biopharmaceutical company that is engaged in the research, development, and commercialization of ophthalmic pharmaceuticals. The Company presently focuses on diseases affecting the back of the eye, or retina, which are well treated with current therapies. Its advanced product candidate is ILUVIEN, an intravitreal implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with DME by delivering sustained sub-microgram levels of FAc, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is implanted in the back of the patient's eye in a non-surgical procedure using an implantation device (the ILUVIEN applicator) employing a 25-gauge needle, which allows for a self-sealing wound. Intravitreal refers to the space inside the eye behind the lens that contains the jelly-like substance called vitreous. In September 2010, the company completed its FAME Study, two Phase 3 pivotal clinical trials on both ILUVIEN and a higher dose FAc intravitreal insert involving 956 patients in sites across the U.S., Canada, Europe and India to assess the efficacy and safety of ILUVIEN in the treatment of DME over a 36 month period. It owned or has licensed four U.S. utility patents, one U.S. design patent and five U.S. patent applications. The Company faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The research, testing, manufacturing and marketing of drug products are subject to extensive regulation by U.S. federal, state and local government authorities, including the FDA and similar entities in other countries.
» More Articles for ALIM

Headlines

Articles On GuruFocus.com
comment on ALIM Mar 02 2013 
Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Oct 31 2014
ALIMERA SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Oct 23 2014
Alimera Sciences to Release Third Quarter 2014 Results Oct 23 2014
Alimera Sciences to Release Third Quarter 2014 Results Oct 23 2014
Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of... Oct 09 2014
ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 01 2014
ALIMERA SCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 30 2014
Why Alimera Sciences (ALIM) Stock Is Up Today Sep 30 2014
Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital Sep 30 2014
ALIMERA SCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 29 2014
Alimera/pSivida's Iluvien Receives FDA Approval for DME Sep 29 2014
Why Alimera Sciences (ALIM) Stock Is Gaining Today Sep 29 2014
Alimera Sciences Inc Extends Gains On FDA News Sep 29 2014
Will Analysts Start Following Alimera After Its FDA Approval? Sep 29 2014
Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For... Sep 29 2014
Alimera, pSivida say FDA clears eye implant Sep 26 2014
ALIMERA SCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 26 2014
Alimera Sciences Receives FDA Approval For ILUVIEN®, The First Long-Term Treatment For Diabetic... Sep 26 2014
ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Sep 22 2014
Alimera Sciences' ILUVIEN® Receives Tenth National Marketing Authorization For The Treatment Of... Sep 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK